BlackRock Fund Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

BlackRock Fund Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.9M	Buy	399,317 +50,951	+15%	+$277K	﹤0.01%	3173
2016 Q3	$2.3M	Buy	348,366 +17,358	+5%	+$92.4K	﹤0.01%	3128
2016 Q2	$1.81M	Buy	331,008 +30,400	+10%	+$485K	﹤0.01%	3208
2016 Q1	$6.43M	Sell	300,608 -13,215	-4%	-$296K	﹤0.01%	2607
2015 Q4	$9.92M	Buy	313,823 +14,033	+5%	+$496K	﹤0.01%	2451
2015 Q3	$10.3M	Buy	299,790 +38,043	+15%	+$1.15M	﹤0.01%	2359
2015 Q2	$8.24M	Buy	261,747 +20,985	+9%	+$618K	﹤0.01%	2618
2015 Q1	$7.06M	Buy	240,762 +43,091	+22%	+$1.01M	﹤0.01%	2637
2014 Q4	$3.66M	Buy	197,671 +28,098	+17%	+$474K	﹤0.01%	3022
2014 Q3	$2.97M	Sell	169,573 -6,977	-4%	-$130K	﹤0.01%	3029
2014 Q2	$3.53M	Buy	+176,550	New	+$3.41M	﹤0.01%	3016

Other funds holding MRTX

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock Fund Advisors's MRTX Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Mirati Therapeutics, Inc. Common Stock (MRTX) stake by 15% in Q4 2016, buying an estimated $277K and bringing the position to 399,317 shares worth $1.9M. The position accounts for ﹤0.01% of the portfolio, ranked #3173.

BlackRock Fund Advisors first reported a position in MRTX in Q2 2014 and has held it in 11 quarters since. The position peaked at $10.3M in Q3 2015. 62 funds tracked by Wall St. Rank hold MRTX as of Q4 2016.

BlackRock Fund Advisors held 399,317 shares of Mirati Therapeutics, Inc. Common Stock worth $1.9M as of Q4 2016.
BlackRock Fund Advisors bought 50,951 Mirati Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $277K.
Mirati Therapeutics, Inc. Common Stock made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3173 holding.
BlackRock Fund Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2014 and has held it in 11 quarters since.
BlackRock Fund Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $10.3M in Q3 2015.
62 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.